低度症的挑战:怀疑,诊断,遗传学,管理和随访
Rodrigo Montero-Lopez1, Mariam R Farman2, Florian Högler2
1Centre for Growth and Osteology, Department of Paediatrics and Adolescent Medicine, Johannes Kepler University Linz, Linz, Austria, rodrigo.monterolopez@kepleruniklinikum.at.
Hormone research in paediatrics
|August 5, 2024
概括
低度症 (HPP) 是一种罕见的遗传疾病,由于ALPL基因变异影响骨健康. 标准化的诊断和管理指南对于改善患者护理和治疗结果至关重要.
科学领域:
- 遗传学 是一个遗传学.
- 生物化学 生化学
- 内分泌学 在内分泌学.
背景情况:
- 低度症 (HPP) 是一种罕见的遗传疾病,由ALPL基因中的功能丧失变异引起.
- 它导致缺陷组织非特异性性酸酶 (ALP) 活性,其特征是血清ALP低,pyridoxal-5-phosphate (PLP) 高.
- 临床范围很广,从周围产生的死亡率到无症状病例,构成诊断和治疗挑战.
研究的目的:
- 突出与低酸性病 (HPP) 相关的诊断和管理挑战.
- 强调需要标准化诊断方法和基于共识的HPP指导方针.
- 讨论分子遗传测试和酶替代疗法 (ERT) 在HPP管理中的作用.
主要方法:
- 对HPP的诊断标准的审查,包括生化特征和临床表现.
- 分析分子遗传测试在HPP诊断中的作用.
- 评估当前的治疗策略,包括酶替代疗法 (ERT) 和对较温和的HPP形式的治疗.
主要成果:
- 诊断依赖于生物化学标记 (低ALP,高PLP) 和骨/骨外表现.
- 分子遗传测试是关键的,但在诊断较轻的病例和将基因型与表型相关联方面仍然存在挑战.
- 酶替代疗法 (ERT) 对严重的HPP有效,而较温和的形式需要细微的管理.
结论:
- 标准化的诊断框架对于统一的HPP诊断至关重要.
- 解决ERT启动,响应评估和长期监测方面的挑战需要精细的指导方针.
- 制定基于共识的指导方针对于提高HPP患者和携带者的临床结果至关重要.
相关概念视频
Chronic Pancreatitis II: Collaborative Care
79
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
79
Pulmonary Hypertension: Classification and Pathogenesis
162
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
162
The Parathyroid Glands
2.0K
The two pairs of parathyroid glands embedded within the posterior surface of the thyroid gland are restricted by a dense capsule around them. These glands comprise two distinct cell populations—parathyroid oxyphil and parathyroid principal cells- pivotal in calcium homeostasis.
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by...
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by...
2.0K
Protein Kinases and Phosphatases
13.1K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.1K
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
151
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
151


